Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial

Table 4

Adverse events.

Event	All	Grades number of patients (% of category)
	Number of patients; (% of total ())	1	2	3	4
Mucositis	3 (43)	2 (67)	1 (33)
Fatigue	3 (43)	1 (33)		2 (67)
Hypertriglyceridemia	3 (43)	1 (33)	2 (67)
Peripheral edema	2 (29)		1 (50)	1 (50)
Anorexia	2 (29)	2 (100)
Diarrhea	2 (29)	1 (50)	1 (50)
Rash	2 (29)	1 (50)	1 (50)
Pneumonia	2 (29)	1 (50)		1 (50)
Liver function disorders	2 (29)	1 (50)	1 (50)
Hypercholesterolemia	2 (29)	1 (50)		1 (50)
Hypophosphatemia	2 (29)	2 (100)
Hypoparathyroidism	2 (29)	2 (100)
Weight loss	1 (14)	1 (100)
Nausea	1 (14)	1 (100)
Vomiting	1 (14)	1 (100)
Constipation	1 (14)	1 (100)
Allergic reaction	1 (14)		1 (100)
Dry skin	1 (14)	1 (100)
Itch	1 (14)		1 (100)
Asthenia	1 (14)	1 (100)
Anemia	1 (14)		1 (100)
Hyperglycemia	1 (14)			1 (100)
Cough	1 (14)		1 (100)
Dyspnea	1 (14)	1 (100)
Pneumonitis	1 (14)			1 (100)

All AEs graded according to Common Terminology Criteria for Adverse Events version 4.0.